| Item 2.02. | Results of Operations and Financial Condition. |
On November 14, 2018, Iterum Therapeutics plc (“Iterum”) issued a press release announcing certain financial results for its third quarter ended September 30, 2018. A copy of the press release is furnished herewith as Exhibit 99.1.
The information in this current report on Form8-K, including the press release attached as Exhibit 99.1 hereto, is being furnished, but shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Iterum, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Non-GAAP Financial Measures
To supplement Iterum’s financial results presented in accordance with U.S. generally accepted accounting principles, or GAAP, Iterum presentsnon-GAAP adjusted net loss (and the related per share measure) to exclude from reported GAAP net loss (and the related per share measure) the $7.5 million milestone payment made to Pfizer on first patient dosing in the SURE 1 clinical trial with oral sulopenem. Iterum believes that the presentation ofnon-GAAP adjusted net loss, when viewed with its results under GAAP and the accompanying reconciliation, provides useful supplementary information to, and facilitates additional analysis by investors, analysts, and Iterum’s management in assessing Iterum’s performance and results from period to period. Thisnon-GAAP measure closely aligns with the way management measures and evaluates Iterum’s performance. Thisnon-GAAP financial measure should be considered in addition to, and not a substitute for, or superior to, net loss or other financial measures calculated in accordance with GAAP.Non-GAAP adjusted net loss is not based on any standardized methodology prescribed by GAAP and represents GAAP net loss, which is the most directly comparable GAAP measure, adjusted to exclude the $7.5 million milestone payment to Pfizer. Because of thenon-standardized definitions ofnon-GAAP financial measures,Non-GAAP adjusted net loss used by Iterum in the accompanying press release and tables therein has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. A reconcilliation ofnon-GAAP adjusted net loss to GAAP net loss has been provided in the tables included in the accompanying press release.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
